Selling stockholders can now begin distributing shares into the market at any time. Expect potential downward pressure as the overhang is worked through. Monitor for a Form 144 or a 424B5 prospectus supplement indicating an actual takedown — that would be the execution signal.
Price Chart
Executive Summary
Quince Therapeutics' S-3 shelf registration (File No. 333-297903) became effective on August 24, 2026. The shelf registers up to 15,470,099 shares of common stock for resale by selling stockholders related to the May 2026 Orphai Therapeutics acquisition and concurrent PIPE — not a primary capital raise. Effectiveness removes the final procedural hurdle for selling stockholders to begin distributing shares, creating a tangible overhang of potential secondary selling into the market.
Key Facts
- S-3 shelf (File No. 333-297903) declared effective on August 24, 2026.
- Registers up to 15,470,099 shares of common stock for resale by selling stockholders.
- Shares stem from the May 2026 Orphai Therapeutics acquisition and concurrent PIPE — no new primary offering.
- Effectiveness follows the S-3/A filed August 5, 2026, which added the legal opinion.
- With a $35M market cap, the registered shares represent a substantial portion of the float, creating a significant overhang.
Financial Impact
Up to 15,470,099 shares registered for resale on a ~$35M market cap — potential dilution overhang of material size relative to current float.
Risk Factors
- Selling stockholders may begin distributing shares immediately, creating supply pressure.
- Registered shares represent a large percentage of the current market cap, amplifying dilution risk.
- No lock-up or resale restrictions disclosed — timing of sales is at the stockholders' discretion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002741 |
| Document: 9999999995-26-002741-index.html | 9999999995-26-002741 |
| Document: 9999999995-26-002741.txt | 9999999995-26-002741 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 8-K | $31.32 $28.59 | ▲ +8.72% | ▲ +7.51% | $30.20 (+3.58%) |
Aug 25, 2026 5w ago | EFFECT | $30.93 $32.11 | ▼ −3.82% | ▼ −4.35% | $30.20 (+2.36%) |
Aug 14, 2026 7w ago | 8-K | $31.34 awaiting T+5 | awaiting T+5 | — | $30.20 (−3.64%) |
Aug 14, 2026 7w ago | Press Release | $31.34 awaiting T+5 | awaiting T+5 | — | $30.20 (−3.64%) |
Aug 5, 2026 8w ago | S-3/A | $28.88 $31.26 | ▲ +8.24% | ▲ +7.89% | $30.20 (+4.57%) |
Jun 11, 2026 16w ago | 3 | $0.9337 $0.9451 | ▲ +1.22% | ▲ +0.55% | $30.20 (+3134.44%) |
May 18, 2026 19w ago | 8-K | $19.90 $24.00 | ▲ +20.60% | ▲ +18.99% | $30.20 (+51.76%) |
Apr 27, 2026 22w ago | DEFA14A | $24.60 $24.60 | · 0.00% | ▼ −1.70% | $30.20 (+22.76%) |
Apr 9, 2026 25w ago | 8-K | $1.24 $1.34 | ▲ +8.06% | ▲ +4.88% | $30.20 (+2335.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access